Target intelligence / Profile preview

Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) (DYRK1A)

Target
DYRK1A
Molecular classification
Enzyme, Protein kinase, Dual-specificity kinase, CMGC kinase family
01

Overview

Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is a highly conserved protein kinase belonging to the CMGC family, located on chromosome 21 in the Down syndrome critical region [1, 3, 13]. It plays a pivotal role in neurodevelopment, cell cycle regulation, and various signaling pathways by phosphorylating a wide range of substrates, including transcription factors and cytoskeletal proteins [2, 4, 6]. DYRK1A is a dosage-sensitive enzyme; its overexpression is a primary driver of cognitive deficits and early-onset Alzheimer's disease in Down syndrome, while its haploinsufficiency leads to a specific syndrome characterized by microcephaly and intellectual disability [5, 18, 22]. In addition to neurodevelopmental roles, DYRK1A is implicated in cancer progression, diabetes (by regulating beta-cell proliferation), and viral infections [1, 6, 16]. Therapeutic strategies primarily focus on small-molecule inhibitors, such as harmine and epigallocatechin gallate (EGCG), which aim to normalize kinase activity in conditions of overexpression [9, 14, 23]. However, maintaining the delicate balance of its activity remains a significant clinical challenge due to its essential role in normal physiology [18, 22].

Other names
DYRK1DYRKMNBMNBHHP86MRD7Dual specificity tyrosine-phosphorylation-regulated kinase 1A
02

Mechanism of action

ATP-competitive inhibition of the kinase domain

03

Biological functions

Signal transductionCell cycle regulationmRNA splicingNeuronal developmentCell proliferationApoptosisDNA damage repairChromatin transcriptionSynaptic plasticity
04

Disease associations

Down syndromeAlzheimer's diseaseParkinson's diseaseCancerDiabetes mellitusIntellectual disabilityMicrocephaly
05

Safety considerations

Dosage sensitivity (risk of microcephaly or intellectual disability from over-inhibition)Off-target effects on other CMGC kinasesPotential for developmental toxicity
06

Interacting drugs

Harmine

6 more in the full profile.

07

Biomarkers

Plasma DYRK1A levelsCerebrospinal fluid Aβ1-42Cerebrospinal fluid tauEEG featuresLaminB1 levels

Beyond the preview

Go deeper on Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) (DYRK1A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) (DYRK1A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call